Autologous adipose-derived stem cells, receive US FDA approval for a second-phase clinical trial (Phase IIb)

Autologous adipose-derived stem cells, receive US FDA approval for a second-phase clinical trial (Phase IIb)

JointStem, a degenerative arthritis treatment agent developed in Korea, became the world’s first adipose-derived stem cells to receive US FDA approval for a second-phase clinical trial (Phase IIb) on January 3.

Read more